TELA Bio (TELA Bio) Inventory-to-Revenue : 0.81 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is TELA Bio Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. TELA Bio's Average Total Inventories for the quarter that ended in Dec. 2023 was $13.74 Mil. TELA Bio's Revenue for the three months ended in Dec. 2023 was $17.00 Mil. TELA Bio's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.81.

TELA Bio's Inventory-to-Revenue for the quarter that ended in Dec. 2023 declined from Sep. 2023 (0.94) to Sep. 2023 (0.81)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. TELA Bio's Days Inventory for the three months ended in Dec. 2023 was 233.35.

Inventory Turnover measures how fast the company turns over its inventory within a year. TELA Bio's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.39.

TELA Bio Inventory-to-Revenue Historical Data

The historical data trend for TELA Bio's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TELA Bio Inventory-to-Revenue Chart

TELA Bio Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory-to-Revenue

Get a 7-Day Free Trial

0.29

0.23

0.20

0.24

0.21

TELA Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Inventory-to-Revenue	Get a 7-Day Free Trial															1.03	1.13	1.01	0.94	0.81

Competitive Comparison of TELA Bio's Inventory-to-Revenue

For the Medical Devices subindustry, TELA Bio's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TELA Bio's Inventory-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TELA Bio's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where TELA Bio's Inventory-to-Revenue falls into.

TELA Bio Inventory-to-Revenue Calculation

TELA Bio's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (A: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )
=	( (11.792	+	13.162)	/	2 )	/	58.453
=	12.477					/	58.453
=	0.21

TELA Bio's Inventory-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (Q: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Revenue (Q: Dec. 2023 )
=	( (14.323	+	13.162)	/	2 )	/	16.998
=	13.7425					/	16.998
=	0.81

TELA Bio (NAS:TELA) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

TELA Bio's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	13.7425	/	5.374	*	365 / 4
	=	233.35

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

TELA Bio's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	5.374	/	13.7425
	=	0.39

TELA Bio Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of TELA Bio's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

TELA Bio (TELA Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TELA Bio Inc (NAS:TELA) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Great Valley Parkway, Suite 24, Malvern, PA, USA, 19355

Website

https://www.telabio.com

TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.

Executives

Gregory A. Firestone	officer: Chief Business Officer	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Roberto Cuca	officer: COO and CFO	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Antony Koblish	director, officer: Chief Executive Officer	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Ew Healthcare Partners Fund 2-a, L.p.	other: See footnotes 1 and 2	280 PARK AVENUE, 27TH FLOOR EAST, NEW YORK NY 10017
Quaker Bioventures Ii Lp	10 percent owner	QUAKER BIOVENTURES, 2929 ARCH STREET, PHILADELPHIA PA 19104
Quaker Bioventures Capital Ii, L.p.	10 percent owner	CIRA CENTER, 2929 ARCH STREET, PHILADELPHIA PA 19104
Lisa N Colleran	director	0NE MILLENIUM WAY, BRANCHBURG NJ 08876
John Nosenzo	director	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Federica F. O'brien	director	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Kurt Azarbarzin	director	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Vincent J Burgess	director	2210 FARADAY AVE #100, CARLSBAD CA 92008
Douglas G Evans	director	1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355